Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

on

IDEAYA Biosciences dosed the first patient in a Phase 1 dose-escalation/expansion clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific TOP1 ADC12

IDE034 was independently developed by Biocytogen and licensed to IDEAYA in July 20241

The first patient dosing triggered a $5 million milestone payment to Biocytogen pursuant to the companies' option and license agreement1

The Phase 1 study is designed to characterize IDE034's safety profile, tolerability, and pharmacokinetic profile as a monotherapy1

IDEAYA plans to evaluate combination regimens with DNA damage response (DDR)-targeting agents, such as its oral PARG inhibitor IDE161, as the program advances1

IDE034 is designed to preferentially internalize in tumor cells co-expressing B7H3 and PTK7, with estimated 30-40% co-expression across several major solid tumors and limited dual expression in normal tissues1

Sources:

1. https://www.marketscreener.com/news/biocytogen-pharmaceuticals-co-ltd-announces-clinical-milestone-with-first-patient-dosed-in-phase-ce7e5cdfde80fe2d

2. https://www.afp.com/en/infos/biocytogen-announces-clinical-milestone-first-patient-dosed-phase-1-trial-ideayas-first-class